chufangao/CTO huggingface dataset:
Clinical trial NCT03029442: The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury
Official title: The Efficacy of Denosumab to Prevent Bone Loss in Ambulatory and Non-ambulatory Motor-Incomplete Patients With Subacute Spinal Cord Injury
Sponsor: James J. Peters Veterans Affairs Medical Center (FED)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Study ended early due to COVID-19
Enrollment: 5.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-04-01
Primary completion date: 2021-12-31
Completion date: 2022-10-06
Plan to share individual participant data: NO
IPD sharing description: An IPD is not desired by the investigators and is not part of the regulatory guidelines at the participating institutions
Clinical trial NCT05623839: A Study of LY3305677 in Participants With Obesity Or Overweight
Official title: A Multiple Dose Titration Study in Participants With Obesity or Overweight to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3305677
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 32.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-11-16
Primary completion date: 2023-06-27
Completion date: 2023-06-27
Plan to share individual participant data: NO
Clinical trial NCT05068856: A Study of HRS2543 in Patients With Advanced Tumors
Official title: A Phase I, Multi-Center, Open Label, Dose Escalation/Expansion Study of HRS2543 in Patients With Advanced Tumors
Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: R\&d strategy adjustment
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-12-28
Primary completion date: 2024-05-15
Completion date: 2024-05-15
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03537612: Sensorial and Physiological Mechanism-based Assessments of Perioperative Pain
Official title: Sensorial and Physiological Mechanism-based Assessments of Perioperative Pain
Acronym: RCT
Sponsor: Shriners Hospitals for Children (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Do to our inability to meet recruitment targets - Sponsor stopped funding. Looking for new sponsor and protocol modifications
Enrollment: 15.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-06-22
Primary completion date: 2022-04-05
Completion date: 2022-04-05
Clinical trial NCT02595996: Propranolol Dose Escalation in Lymphedema in Patients
Official title: An Intra-patient Dose Escalation Study of Propranolol in Patients With Lymphedema
Sponsor: Columbia University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of funding
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-06-07
Primary completion date: 2020-10-08
Completion date: 2020-10-08
Limitations and caveats: Study terminated due to lack of funding. Data was not analyzed or disclosed due to subject confidentiality being an issue (n=1).
Clinical trial NCT03963973: A 28 Day Parallel Group Study to Assess the Effects of RDN-929
Official title: A Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetic (PK) Profile of Multiple Oral Doses of RDN-929 in Healthy Older Adults
Sponsor: Alkermes, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Participants no longer receiving intervention
Enrollment: 7.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-16
Primary completion date: 2020-01-22
Completion date: 2020-01-22
Plan to share individual participant data: NO
Clinical trial NCT04441671: Oral Pyrophosphate Absorption in PXE Disease
Official title: Oral Disodiumpyrophosphate (Na2H2PPi) Absorption in Pseudoxanthoma Elasticum (PXE)
Sponsor: Tampere University Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Withdrawn
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-12-08
Primary completion date: 2021-04-01
Completion date: 2021-04-01
Plan to share individual participant data: NO
IPD sharing description: Only anonymized data can be shared
Clinical trial NCT04432272: ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS)
Official title: ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS)
Acronym: ABACCuS
Sponsor: William Beaumont Hospitals (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The EUA for CCP was updated by FDA, stipulating that only high titer units be used. This study required untitered units. The study became infeasible
Enrollment: 71.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-16
Primary completion date: 2020-11-13
Completion date: 2020-11-28
Limitations and caveats: Early termination due to changes in the Emergency Use Authorization for plasma during COVID-19. All plasma was labeled either low titer or high titer. The protocol required untitered plasma be used, which resulted in inability to complete the study and early termination.
Plan to share individual participant data: NO
Clinical trial NCT04447417: Dupilumab Skin Barrier Function Study in Atopic Dermatitis
Official title: Open Label Exploratory Study to Evaluate the Effect of Dupilumab on Skin Barrier Function in Patients With Moderate to Severe Atopic Dermatitis
Acronym: BALISTAD
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 52.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-16
Primary completion date: 2021-06-17
Completion date: 2021-06-17
Baseline population: Analysis was performed on safety population: all enrolled participants who actually received at least one dose of investigational medicinal product (IMP) or had at least one transepidermal water loss (TEWL)/skin tape stripping (STS) assessment and all healthy volunteers who had at least one TEWL/STS assessment performed.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org.
Clinical trial NCT03347188: A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraumatic Headache (PTH)
Official title: A Phase 2, Multicenter, Randomized, Proof-of-Concept, Double-Blind, Placebo-Controlled, Parallel-Group Study, Including an Open-Label Period, Evaluating the Efficacy and Safety of 1 Subcutaneous Dose Regimen of Fremanezumab for the Treatment of Posttraumatic Headache (PTH)
Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 87.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-12-18
Primary completion date: 2020-03-13
Completion date: 2020-06-03
Baseline population: Intent-to-treat (ITT) analysis set included all randomized participants.
Plan to share individual participant data: NO
Clinical trial NCT02770170: Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis
Official title: A Double-blind, Randomised, Placebo-controlled Trial Evaluating the Effect of BI 655064 Administered as Sub-cutaneous Injections, on Renal Response After One Year of Treatment, in Patients With Active Lupus Nephritis
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 121.0 (ACTUAL)
Number of arms: 4.0
Start date: 2016-05-16
Primary completion date: 2020-06-23
Completion date: 2020-08-18
Baseline population: Treated set (TS): This patient set included all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.
Clinical trial NCT04996056: An Open-Label, Randomized Pilot Study Comparing the Safety of a Single Dose of TNX-1300 to Usual Care (UC) Alone for the Treatment of Signs and Symptoms of Acute Cocaine Intoxication in Male Emergency Department (ED) Subjects
Official title: An Open-Label, Randomized Pilot Study Comparing the Safety of a Single Dose of TNX-1300 to Usual Care (UC) Alone for the Treatment of Signs and Symptoms of Acute Cocaine Intoxication in Male Emergency Department (ED) Subjects
Sponsor: Tonix Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Not able to recruit qualified participants
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-09-03
Primary completion date: 2022-06-16
Completion date: 2022-06-16
Clinical trial NCT02770807: Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients
Official title: Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effects of Intra-Erythrocyte Dexamethasone Sodium Phosphate on Neurological Symptoms in Patients With Ataxia Telangiectasia
Acronym: ATTeST
Sponsor: Quince Therapeutics S.p.A. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 176.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-03-02
Primary completion date: 2021-05-13
Completion date: 2021-05-13
Baseline population: Safety (SAF): all patients who received any amount of randomized treatment (also referred to as the ITT ) Full Analysis Set (FAS): All randomized pts who received at least 1 dose of study medication and had at least one post-baseline efficacy assessment of the primary efficacy variable (also referred to as mITT ) Per Protocol (PP): all pts enrolled fulfilled all Inclusion/Exclusion criteria, did not have any major protocol violations, and completed the Initial Treatment Period of the study
Plan to share individual participant data: NO
Clinical trial NCT03866200: Resveratrol Trial for Relief of Pain in Pseudoachondroplasia
Official title: Resveratrol Trial for Relief of Pain in Pseudoachondroplasia
Sponsor: The University of Texas Health Science Center, Houston (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Inability to recruit target number
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-29
Primary completion date: 2020-10-28
Completion date: 2020-10-28
Plan to share individual participant data: NO
Clinical trial NCT03271229: Conventional Platelet-Rich Plasma Versus Concentrated Bone Marrow Stem Cell Injections for Osteoarthritis of the Knee
Official title: A Randomized, Single-Blinded, Controlled Trial Comparing Conventional Platelet Rich Plasma (PRP) to Concentrated Bone Marrow Aspirate (BMAC) for Osteoarthritis of the Knee
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-09-30
Primary completion date: 2021-01-31
Completion date: 2021-01-31
Plan to share individual participant data: NO
Clinical trial NCT03917459: COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure
Official title: A Randomized, Double-blind, Active-controlled Study to Assess the Effect of Sacubitril/Valsartan Compared With Enalapril to Improve Erectile Function in Patients With Heart Failure With Reduced Ejection Fraction and Erectile Dysfunction
Acronym: CONFIDENCE-HF
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 27.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-04-16
Primary completion date: 2021-05-25
Completion date: 2021-05-25
Baseline population: A total of 27 patients were included in the Full Analysis Set (FAS) and safety set.
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT03124459: Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease
Official title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Types 1 and X
Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: (Investigation of ACE-083 for use in patients with CMT is being discontinued as it did not achieve functional secondary endpoints in the A083-03 trial.
Enrollment: 63.0 (ACTUAL)
Number of arms: 5.0
Start date: 2017-07-31
Primary completion date: 2020-03-11
Completion date: 2020-03-11
Baseline population: The Full Analysis Set includes all randomized patients who have received at least 1 dose of study drug (includes placebo). Additionally, the participants in the Open-Label portion of Part 2 are a sub-set of the participants that enrolled and then subsequently completed the double-blind placebo controlled portion of Part 2. The open-label baseline measures are captured separately.
Limitations and caveats: The study was terminated because the statistically significant increase in total muscle volume (TMV) failed to translate to statistically significant improvements in functional or disease-related quality of life secondary endpoints in the study.
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03987750: Safinamide for Levodopa-induced Dyskinesia (PD-LID)
Official title: A Phase 3, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of 2 Doses of Safinamide Compared to Placebo in the Treatment of LID in PD Patients With Motor Fluctuations
Sponsor: Zambon SpA (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: drug development plan has been updated
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-10-31
Primary completion date: 2021-04-30
Completion date: 2021-05-31
Clinical trial NCT02378623: Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli
Official title: PARADOX Trial: A Prospective, Double-Blind, Randomized Controlled Trial in Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli
Acronym: PARADOX
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Sponsor withdrew funding - May 2016
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-05-31
Primary completion date: 2020-01-31
Completion date: 2020-01-31
Clinical trial NCT03593213: Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia
Official title: A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: FDA Released Allergan from this post marketing requirement
Enrollment: 587.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-07-30
Primary completion date: 2021-02-11
Completion date: 2021-02-11
Baseline population: Double-blind Safety Population included all participants who took at least 1 dose of cariprazine during and double-blind treatment period.
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: For details on when studies are available for sharing, please refer to the link below.
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.
Clinical trial NCT03090412: Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer
Official title: A Randomized Multicenter Phase II Study Using (2-1[Heyloxyethyl]-2-Devinylpyropheophorbide-a) (HPPH) With PDT Versus Standard of Care Surgery for Patients With T1/T2 N0 Squamous Cell Carcinoma of the Oral Cavity
Sponsor: Roswell Park Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: low accrual
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-07
Primary completion date: 2021-08-01
Completion date: 2021-08-06
Clinical trial NCT04676412: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study
Official title: A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) in Participants With Treatment-naïve, Metastatic Nonsmall Cell Lung Cancer (NSCLC) Whose Tumors Have a Tumor Proportion Score (TPS) Greater Than or Equal to 1% (LEAP-007)
Acronym: LEAP-007
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 27.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-23
Primary completion date: 2021-05-19
Completion date: 2024-03-29
Baseline population: All Chinese participants who were randomized to the global study (NCT03829332) or to the extension portion.
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT04425655: Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.
Official title: A Phase II Trial of Fludarabine in Combination With Daunorubicin and Cytarabine Liposome for Adults With Newly-diagnosed Acute Myeloid Leukemia: University of California Hematologic Malignancies Consortium Protocol 1914
Sponsor: University of California, San Diego (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Original investigator for the trial has left
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-08-05
Primary completion date: 2022-07-01
Completion date: 2022-07-01
Clinical trial NCT04034615: The Long-term Effect of Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars
Official title: A Phase II, Randomized, Placebo-Controlled Study of the Long-term Efficacy of Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars
Sponsor: Maternal and Child Health Hospital of Foshan (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: The pandemic resulted in no enrollments。
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-05-20
Primary completion date: 2021-12-01
Completion date: 2022-06-01
Clinical trial NCT03906136: AScalate: Treat-to-target in Axial Spondyloarthritis
Official title: A Randomized, Open Label Multicenter Trial to Investigate the Efficacy of a Treat-to-target (T2T) Treatment Strategy With Secukinumab (AIN457) as a First-line Biologic Compared to a Standard-of-care (SOC) Treatment Over 36 Weeks in Patients With Active Axial Spondyloarthritis (axSpA)
Acronym: AScalate
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 305.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-04
Primary completion date: 2022-02-04
Completion date: 2022-09-22
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT04561180: Study to Evaluate the Efficacy and Safety of EG-009A Compared to DEX in Patients With COVID-19 Pneumonia
Official title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of EG-009A Compared to Dexamethasone in Patients With Moderate/Severe (Non-intubated, Non-mechanical Ventilation) COVID-19 Pneumonia
Sponsor: Evergreen Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No patients COVID-19 morbidity decreased.
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-03-04
Primary completion date: 2023-05-01
Completion date: 2023-05-01
Clinical trial NCT03511664: Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
Official title: VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Acronym: VISION
Sponsor: Endocyte (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 831.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-05-29
Primary completion date: 2021-01-27
Completion date: 2023-12-14
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT03027167: Outcomes Study in Patients Receiving Aspirin With Mechanical Compression Devices Versus Aspirin Alone Following Knee and Hip Arthroplasty
Official title: Outcomes Study to Determine the Incidence of Symptomatic DVT/PE in Patients Receiving Aspirin With Mechanical Compression Devices Versus Aspirin Alone Following Knee and Hip Arthroplasty
Acronym: PDAS
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-01-31
Primary completion date: 2019-01-31
Completion date: 2023-01-31
Plan to share individual participant data: UNDECIDED